Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 1/20 | 0.58 |
| ▸ | AOC3 | Q16853 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | EDNRB | P24530 | 1/20 | 0.44 |
| ▸ | MC4R | P32245 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbamic Acid SCHEMBL6362690 | 1.00 | BCAT2 (0.58) | BCAT2AOC3LMNAKDM4EL3MBTL1 | |
| Bicarbonate SCHEMBL2836236 | 0.91 | LMNA (0.54) | BCAT2AOC3LMNAKDM4EL3MBTL1 | |
| SCHEMBL30957022 | 0.89 | LMNA (0.61) | BCAT2AOC3LMNAKDM4EL3MBTL1 | |
| SCHEMBL24750 | 0.89 | LMNA (0.61) | BCAT2AOC3LMNAKDM4EL3MBTL1 | |
| SCHEMBL1947849 | 0.89 | LMNA (0.61) | BCAT2AOC3LMNAKDM4EL3MBTL1 | |
| SCHEMBL3413766 | 0.89 | LMNA (0.61) | BCAT2AOC3LMNAKDM4EL3MBTL1 | |
| SCHEMBL8366350 | 0.89 | LMNA (0.61) | BCAT2AOC3LMNAKDM4EL3MBTL1 | |
| SCHEMBL29588786 | 0.86 | LMNA (0.58) | BCAT2AOC3LMNAKDM4EL3MBTL1 | |
| SCHEMBL18813398 | 0.86 | LMNA (0.58) | BCAT2AOC3LMNAKDM4EL3MBTL1 | |
| SCHEMBL27887405 | 0.86 | LMNA (0.58) | BCAT2AOC3LMNAKDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0907635-B1 | HALOGEN SUBSTITUTED CARBAMATE COMPOUNDS FROM 2-PHENYL-1,2-ETHANEDIOL | SK CORP (KR) | 2002-09-25 | — | — | EP | claimed |
| US-5854283-A | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol | YUKONG LIMITED (KR) | 1998-12-29 | — | — | US | claimed |
| EP-1404312-B1 | CARBAMATE COMPOUNDS FOR USE IN THE TREATMENT OF PAIN | ORTHO MCNEIL PHARM INC (US) | 2010-12-29 | — | — | EP | disclosed |
| CN-101568362-A | Methods for treating depression | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-28 | — | — | CN | disclosed |
| US-20090234003-A1 | CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING ANXIETY DISORDERS | PLATA-SALAMAN CARLOS R | 2009-09-17 | — | — | US | disclosed |
| US-20090005442-A1 | CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING NEURODEGENERATIVE DISORDERS | SK BIOPHARMACEUTICALS CO., LTD (KR) | 2009-01-01 | — | — | US | disclosed |
| EP-1411917-B1 | CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING MOVEMENT DISORDERS | ORTHO MCNEIL PHARM INC (US) | 2007-08-08 | — | — | EP | disclosed |
| EP-1383489-B1 | CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING NEURODEGENERATIVE DISORDERS | ORTHO MCNEIL PHARM INC (US) | 2007-05-09 | — | — | EP | disclosed |
| EP-1401424-B1 | CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING PSYCHOTIC DISORDERS | ORTHO MCNEIL PHARM INC (US) | 2006-11-29 | — | — | EP | disclosed |
| US-7078436-B2 | Carbamate compounds for use in preventing or treating anxiety disorders | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2006-07-18 | — | — | US | disclosed |
| EP-1399144-B1 | CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING ANXIETY DISORDERS | ORTHO MCNEIL PHARM INC (US) | 2006-04-26 | — | — | EP | disclosed |
| US-20020156127-A1 | Carbamate compounds for use in the treatment of pain | SK BIOPHARMACEUTICALS CO., LTD (KR) | 2002-10-24 | — | — | US | disclosed |
| US-20020151585-A1 | Carbamate compounds for use in preventing or treating movement disorders | SK BIOPHARMACEUTICALS CO., LTD (KR) | 2002-10-17 | — | — | US | disclosed |
| US-20020143053-A1 | Carbamate compounds for use in preventing or treating anxiety disorders | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-10-03 | — | — | US | disclosed |
| WO-2002067927-A1 | CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING PSYCHOTIC DISORDERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| WO-2002067926-A1 | CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING MOVEMENT DISORDERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| WO-2002067925-A1 | CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING NEURODEGENERATIVE DISORDERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| WO-2002067923-A1 | CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING ANXIETY DISORDERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| WO-2002067922-A1 | CARBAMATE COMPOUNDS FOR USE IN THE TREATMENT OF PAIN | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| US-5698588-A | OPTICALLY PURE ENANTIOMERIC FORM; TREATING CENTRAL NERVOUS SYSTEM DISORDERS | YUKONG LIMITED (KR) | 1997-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156127-A1 | Carbamate compounds for use in the treatment of pain | CNR1, CBR3, CNR2 | BCAT2 623/4885AOC3 403/4885LMNA 3944/4885 |
| US-20090005442-A1 | CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING NEURODEGENERATIVE DISORDERS | BCHE, CBR3, C9 | BCAT2 493/4885AOC3 27/4885LMNA 1544/4885 |
| US-20090234003-A1 | CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING ANXIETY DISORDERS | CBR3, CBR1, CNR1 | BCAT2 208/4885AOC3 49/4885LMNA 1908/4885 |
| US-20020151585-A1 | Carbamate compounds for use in preventing or treating movement disorders | CHAT, CES2, SLC6A3 | BCAT2 411/4885AOC3 110/4885LMNA 2953/4885 |
| US-20020143053-A1 | Carbamate compounds for use in preventing or treating anxiety disorders | CBR1, CNR1, CBR3 | BCAT2 149/4885AOC3 115/4885LMNA 2475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.